Qiagen’s outgoing chief executive Thierry Bernard, M.D., told investors the company does not “comment on rumors” as takeover ...

Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to ...

Applied Medical has been awarded $382 million in damages from Medtronic after a U.S. District Court jury in California ...

Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this ...

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...

Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off ...